Niu Quan, Lu Youyi, Xu Shigao, Shi Qun, Guo Baoyu, Guo Zhe, Huang Tianbao, Wu Yinxia, Yu Junjie
Department of Dalian Medical University, Dalian, Liaoning, People's Republic of China.
Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, People's Republic of China.
Cancer Manag Res. 2018 Oct 11;10:4479-4489. doi: 10.2147/CMAR.S175286. eCollection 2018.
Bladder neuroendocrine carcinomas (BNECs) are relatively a rare type of tumor. The aim of this study was to examine the clinicopathological characteristics and predictors of survival outcomes of patients with BNECs based on the analysis of the national Surveillance, Epidemiology, and End Results (SEER) database.
Kaplan-Meier analysis with log-rank test was used for survival comparisons. Multivariate Cox regression model was employed to analyze the effect of different treatments on overall survival (OS) and cancer-specific survival (CSS).
A total of 910 patients were identified between 2004 and 2014. Overall, 648 (71.2%) patients had small cell neuroendocrine carcinoma (SCNEC), 35 (3.8%) had large cell neuroendocrine carcinoma (LCNEC), 10 (1.1%) had carcinoid tumor (well-differentiated neuroendocrine tumor), 16 (1.8%) had paraganglioma/pheochromocytoma (PGL/PHEO), 619 (68.0%) had a poorly differentiated or undifferentiated histology grade, 214 (23.5%) presented with metastatic disease, 586 (64.4%) underwent transurethral ablation/destruction for bladder tumor, and 245 (26.9%) had partial/total cystectomy. Cystectomy+chemotherapy+radiotherapy (CCR) has the highest long-term survival rate among various treatments. The 1-, 3-, and 5-years CSS of CCR were 56%, 56%, and 56%, respectively. By using multivariable Cox proportional hazard model, age, histology, N stage, SEER stage, tumor size, radiotherapy, chemotherapy, and local treatment of the primary site were identified as independent predictors for OS and CSS; all <0.05.
In BNEC, SCNEC has an absolute advantage in number. SCNEC/LCNEC tend to be older men. PGL/PHEO and carcinoid tumors have younger mean ages, earlier tumor stages, and better prognosis than SCNEC/LCNEC. Surgery, radiotherapy and chemotherapy are better than conservative treatment. However, whatever cystectomy or bladder sparing, chemotherapy should be a major component of treatment.
膀胱神经内分泌癌(BNECs)是一种相对罕见的肿瘤类型。本研究旨在通过分析美国国家癌症监测、流行病学和最终结果(SEER)数据库,探讨BNECs患者的临床病理特征及生存结局的预测因素。
采用Kaplan-Meier分析和对数秩检验进行生存比较。采用多变量Cox回归模型分析不同治疗方法对总生存期(OS)和癌症特异性生存期(CSS)的影响。
2004年至2014年间共纳入910例患者。总体而言,648例(71.2%)患者为小细胞神经内分泌癌(SCNEC),35例(3.8%)为大细胞神经内分泌癌(LCNEC),10例(1.1%)为类癌肿瘤(高分化神经内分泌肿瘤),16例(1.8%)为副神经节瘤/嗜铬细胞瘤(PGL/PHEO),619例(68.0%)组织学分级为低分化或未分化,214例(23.5%)出现转移性疾病,586例(64.4%)因膀胱肿瘤接受经尿道切除/破坏术,245例(26.9%)接受部分/全膀胱切除术。在各种治疗方法中,膀胱切除术+化疗+放疗(CCR)的长期生存率最高。CCR的1年、3年和5年CSS分别为56%、56%和56%。通过多变量Cox比例风险模型,年龄、组织学类型、N分期、SEER分期、肿瘤大小、放疗、化疗以及原发部位的局部治疗被确定为OS和CSS的独立预测因素;均P<0.05。
在BNEC中,SCNEC在数量上具有绝对优势。SCNEC/LCNEC患者多为老年男性。PGL/PHEO和类癌肿瘤的平均年龄较年轻,肿瘤分期较早,预后优于SCNEC/LCNEC。手术、放疗和化疗优于保守治疗。然而,无论采用膀胱切除术还是保留膀胱,化疗都应是治疗的主要组成部分。